I would like to receive Nasdaq communications related to Products, Industry News and Events.You can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy. Posted by Danessa Lincoln on Oct 1st, 2020 // Comments off. PEG Ratios above 1 indicate that a company could be overvalued. SLP: What does Argus have to say about SLP? 59.61% of the stock of Simulations Plus is held by institutions. Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Simulations Plus has only been the subject of 2 research reports in the past 90 days. This suggests a possible upside of 18.8% from the stock's current price. In the past three months, Simulations Plus insiders have sold more of their company's stock than they have bought. Do Not Sell My Information. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. View Simulations Plus' dividend history. Before it's here, it's on the Bloomberg Terminal. Simulations Plus trades on the NASDAQ under the ticker symbol "SLP.". MarketBeat's community ratings are surveys of what our community members think about Simulations Plus and other stocks. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Simulations Plus has only been increasing its dividend for 1 years. SLP stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, 6 Meridian, Harbour Capital Advisors LLC, State of Alaska Department of Revenue, USA Financial Portformulas Corp, Campbell & CO Investment Adviser LLC, and Crossmark Global Holdings Inc.. View insider buying and selling activity for Simulations Plus. Lancaster, CA 93534 Several institutional investors have recently made changes to their positions in the company. The scores are based on the trading styles of Value, Growth, and Momentum. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Over the past month, the stock increased by 35.70%, and in the past year, by 107.44%. Finally, FinTrust Capital Advisors LLC acquired a new position in Simulations Plus during the first quarter valued at $106,000. © 2020, Nasdaq, Inc. All Rights Reserved. Yes! The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. Specifically, they have bought $0.00 in company stock and sold $3,173,040.00 in company stock. A sector with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. The company was founded in 1996 and is headquartered in Lancaster, California. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%. View all competitors. Since then, SLP shares have increased by 131.3% and is now trading at $69.84. The stock has a fifty day moving average of $63.16 and a two-hundred day moving average of $51.50. Simulations Plus (SLP) is the IBD Stock Of The Day as investors take massive profits from the highflying medical technology stock. The P/E ratio of Simulations Plus is 139.68, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 65.98. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? They issued an “outperform” rating and a $79.00 price objective for the company. Simulations Plus has received 51.67% “underperform” votes from our community. 28.96% of the stock is owned by insiders. Identify stocks that meet your criteria using seven unique stock screeners. Hosting the call today is Simulations Plus… Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Earnings for Simulations Plus are expected to grow by 16.98% in the coming year, from $0.53 to $0.62 per share. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Zacks Investment Research lowered Simulations Plus from a “buy” rating to a “hold” rating in a report on Wednesday, September 16th. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. Shares of SLP stock opened at $75.36 on Tuesday. Simulations Plus' stock was trading at $30.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). The technology company earned $12.30 million during the quarter, compared to analysts' expectations of $10.58 million. The stock has a fifty day moving average of $63.16 and a two-hundred day moving average of $51.50. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,221 shares of the technology company’s stock valued at $78,000 after buying an additional 1,241 shares during the period. We use cookies to understand how you use our site and to improve your experience. node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}, Do Not Sell My Personal Information (CA Residents Only). The technique has proven to be very useful for finding positive surprises. ZacksTrade and Zacks.com are separate companies. United States. 59.61% of the stock is currently owned by institutional investors. var dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /^([^@\s]+)@((?:[-a-z0-9]+\. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. also free. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Zacks Style Scores Education - Learn more about the Zacks Style Scores. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. High institutional ownership can be a signal of strong market trust in this company. The P/E ratio of Simulations Plus is 139.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.66. Touch device users, explore by touch or with swipe gestures. Want to see which stocks are moving? View our earnings forecast for Simulations Plus. Simulations Plus has a 1 year low of $26.00 and a 1 year high of $76.24. Please log in to your account or sign up in order to add this asset to your watchlist. There may be delays, omissions, or inaccuracies Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Only 28.96% of the stock of Simulations Plus is held by insiders. Neither Zacks Investment The … The Zacks Rank has been called the Billion Dollar Secret. US Bancorp DE raised its position in Simulations Plus by 51.8% during the second quarter. Simulations Plus is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. (Add your “underperform” vote.). Shareholders of record on Monday, October 26th will be given a dividend of $0.06 per share on Monday, November 2nd. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. SLP has been the subject of several other research reports. See what's happening in the market right now with MarketBeat's real-time news feed. The firm has a market capitalization of $1.34 billion, a PE ratio of 150.72, a price-to-earnings-growth ratio of 6.76 and a beta of -0.19. The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it entered into a collaborative research agreement with a large pharmaceutical company to evaluate the new AIDD Module in the recently launched version of ADMET Predictor ®. View which stocks are hot on social media with MarketBeat's trending stocks report. View analyst ratings for Simulations Plus. In other news, Director Walter S. Woltosz sold 24,000 shares of the business’s stock in a transaction on Monday, July 27th. If you do not, click Cancel. 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last year. Simulations Plus has a 1 year low of $26.00 and a 1 year high of $76.24. 3 Wall Street analysts have issued 12 month price targets for Simulations Plus' stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Simulations Plus has a market capitalization of $1.24 billion and generates $33.97 million in revenue each year. All rights reserved. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. See Zacks' prediction free. Meeder Asset Management Inc. raised its position in Simulations Plus by 11,046.2% during the first quarter.